Tenofovir Disoproxil Fumarate is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Chia Tai Tianqing Pharmaceutical Group Co., Ltd (1). The most-studied condition is Chronic Hepatitis B.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
NCT06356662 · ClinicalTrials.gov ↗ · Parkinson Disease
|
Phase 1 | Recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | China |
|
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
NCT07797231 · ClinicalTrials.gov ↗ · Chronic Hepatitis B
|
Phase 3 | Not yet open | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 |
| The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Tenofovir Disoproxil Fumarate as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd (1) and The Fourth Affiliated Hospital of Zhejiang University School of Medicine (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tenofovir Disoproxil Fumarate works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tenofovir Disoproxil Fumarate works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tenofovir Disoproxil Fumarate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.